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Abstract
Background: Given that there is a possibility of a human H5N1 pandemic and the fact that the recent H5N1 viruses are
resistant to the anti-viral drugs, newer strategies for effective therapy are warranted. Previous studies show that single mAbs
in immune prophylaxis can be protective against H5N1 infection. But a single mAb may not be effective in neutralization of
a broad range of different strains of H5N1 and control of potential neutralization escape mutants.
Methods/Principal Findings: We selected two mAbs which recognized different epitopes on the hemagglutinin molecule.
These two mAbs could each neutralize in vitro escape mutants to the other and in combination could effectively neutralize
viruses from clades 0, 1, 2.1, 2.2, 2.3, 4, 7 and 8 of influenza A H5N1 viruses. This combination of chimeric mAbs when
administered passively, pre or post challenge with 10 MLD50 (50% mouse lethal dose) HPAI H5N1 influenza A viruses could
protect 100% of the mice from two different clades of viruses (clades 1 and 2.1). We also tested the efficacy of a single dose
of the combination of mAbs versus two doses. Two doses of the combination therapy not only affected early clearance of
the virus from the lung but could completely prevent lung pathology of the H5N1 infected mice. No escape variants were
detected after therapy.
Conclusions/Significance: Our studies provide proof of concept that the synergistic action of two or more mAbs in
combination is required for preventing the generation of escape mutants and also to enhance the therapeutic efficacy of
passive therapy against H5N1 infection. Combination therapy may allow for a lower dose of antibody to be administered for
passive therapy of influenza infection and hence can be made available at reduced economic costs during an outbreak.
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Introduction
The recent emergence of H5N1 strains of influenza A virus and
the high mortality caused by them in humans has raised concerns
for the possibility of a future influenza pandemic. Present vaccine
strategies have been hindered by antigenic variation of the
influenza strains [1]. Vaccine strategies requiring endogenous
synthesis of antibodies will not provide the immediate protection
needed against H5N1 infections in the event of a pandemic.
Antiviral therapy has received much attention during these
situations. However, currently available anti-viral treatment
options are limited [2]. Isolation of drug-resistant viral strains
[3,4] in the recent past warrants an urgent need for alternative
strategies for treatment and prophylaxis. Passive administration of
antibodies against neutralizing epitopes of H5N1 may be an
attractive alternative to active vaccination of humans, in particular
for those individuals who are at high risk from influenza infection,
viz. the immuno-compromised patients or the elderly who do not
respond well to active immunization [5].
Antibody based therapy is one of the alternative approaches for
the immunoprophylaxis or the treatment of influenza and other
infections. Passive administration of polyclonal antibodies against
H5N1 has been shown to be protective in several non-primate and
human models of infection [6]. Passive immunization by
transfusion of human convalescent sera was associated with 50%
reduction in mortality during an influenza pandemic and was
shown to be effective against H5N1 influenza A viral infection
[6,7]. Equine F (ab’) 2 fragments specific for H5N1 have been used
for efficacious prophylaxis and therapy in a mouse model [8].
Murine monoclonal antibodies (mAbs) against fusion peptide of
hemagglutinin (HA) of H5N1 influenza have been shown in
passive transfer experiments to protect mice from infection by
reduction of viral replication [9]. Thus passive administration of
mAbs prior to or after influenza infection has the potential
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individuals immediately. Murine mAbs were used in initial clinical
trials. The efficacy of these mAbs was hampered by several
problems including their diminished serum half-life and the
development of human anti-mouse antibodies (HAMA) [10]. To
counter this problem, several strategies have been devised
including the generation of chimeric, humanized and human
mAbs.
Currently, there has been a lot of focus on therapeutic
approaches using neutralizing antibodies against the HA1 protein
of the influenza virus. This protein is easy to target as it is on the
surface of the virus and antibodies against this protein can
neutralize the virus efficiently. MAb prophylaxis, targeting the HA
protein, may be an effective means of controlling an influenza
outbreak. Passive immunoprophylaxis and therapy with a single
neutralizing humanized or human mAb was efficacious against
lethal challenge with specific strains of H5N1 virus [11,12]. It is
important that any mAb product should offer broad protection
against all circulating strains of H5N1 influenza and should
prevent the selection of neutralization escape mutants in vivo.A
single monoclonal antibody may not be efficient in meeting the
above criteria.
Several factors are important in forming an effective combina-
tion of mAbs in the prophylactic and therapeutic regimen against
H5N1 influenza infection. These include inclusion of an ideal pair
of complementing monoclonal antibodies, optimizing the number
of doses, time intervals in between doses and the duration of
therapy. The mAbs included in the combination therapy should
target distinct regions on the antigen with non overlapping
epitopes and should be able to complement each other in a
treatment regimen [13,14]. In the present study, we focus on the
selection of a pair of mAbs against two different neutralizing
epitopes of H5N1 and their chimerization. We evaluate the
prophylactic and therapeutic efficacy of the combination therapy
using the chimeric mAbs in a murine model, experimentally
challenged with two distinct phylogenetic clades of highly
pathogenic H5N1 viruses.
Materials and Methods
Viruses
H5N1 human influenza viruses from clade 2.1 A/Indonesia/
CDC669/2006, A/Indonesia/TLL013/2006, A/Indonesia/
CDC540/2006, A/Indonesia/CDC594/2006 and one avian
strain A/Indonesia/TLL014/2006 were obtained from the
Ministry of Health (MOH), Republic of Indonesia. The other
subtypes of influenza A viruses, H3N2 (A/chicken/Singapore/
Sin/92) and H7N1 (A/common iora/Indonesia/F89/11/95) were
obtained from the Agri-Food and Veterinary Authority (AVA) of
Singapore. The H5N1 viruses from different phylogenetic clades/
subclades were rescued by Reverse Genetics [15]. Briefly, the
hemagglutinin (HA) and neuraminidase (NA) genes of H5N1
viruses from clades 0, 1, 2.1, 2.2, 2.3, 4, 7 and 8 (Table 1) were
synthesized (GenScript, USA) based on the sequence from the
NCBI influenza Database. The synthetic HA and NA genes were
cloned into a dual-promoter plasmid for influenza A reverse
genetics [15]. The dual-promoter plasmids were obtained from
Center for Disease Control and Prevention, Atlanta, GA, USA.
Reassortant viruses were rescued by transfecting plasmids
containing HA and NA along with the remaining six influenza
genes derived from A/Puerto Rico/8/34 (H1N1) into co-cultured
293T and MDCK cells using Lipofectamine 2000 (Invitrogen
Corp.). At 72 h post-transfection the culture medium was
inoculated into embryonated eggs or MDCK cells. The HA and
NA genes of reassortant viruses from the second passage were
sequenced to confirm presence of introduced HA and NA genes
and the absence of mutations. Stock viruses were propagated in
the allantoic cavity of 11 day-old embryonated eggs [16], virus
containing allantoic fluid was harvested and stored in aliquots at
280uC. Virus content was determined by standard hemaggluti-
nation (HA) assay [17]. All experiments with highly pathogenic
viruses were conducted in a biosafety level 3 (BSL-3) containment
facility in compliance with CDC/NIH and WHO recommenda-
tions [18,19].
Production and characterization of mAbs
BALB/c mice were immunized twice subcutaneously at
intervals of 2 weeks with purified formalin inactivated A/
Indonesia/CDC669/2006 or A/Indonesia/TLL014/2006 anti-
gen with adjuvant (SEPPIC, France). Mice were boosted with the
same viral antigen, 3 days before the fusion of splenocytes with
SP2/0 cells [20]. The fused cells were seeded in 96-well plates, and
their supernatants were screened by immunofluorescence assays as
described below. The hybridomas that produced the mAbs were
cloned by limiting dilution at least three times. The positive mAbs
were tested for their hemagglutination inhibition activity as
described below. Immunoglobulins from selected positive mAbs
were isotyped using a commercial isotyping kit (Amersham
Bioscience, England) as described in the manufacturer’s protocol.
Immunofluorescence assay (IFA)
MDCK cells cultured in 96-well plates were infected with AIV
H5N1 strains. At 24–48 h post-infection, the cells were fixed with
4% paraformaldehyde for 30 min at room temperature and
washed thrice with phosphate buffered saline (PBS), pH 7.4. Fixed
cells were incubated with hybridoma culture supernatant at 37uC
for 1 h, rinsed with phosphate buffered saline (PBS) and then
incubated with a 1:40 dilution of fluorescein isothiocyanate
(FITC)-conjugated rabbit anti-mouse Immunoglobulin (Dako,
Denmark). Cells were rinsed again in PBS and antibody binding
was evaluated by wide-field epi-fluorescence microscopy (Olympus
IX71) [21].
Table 1. Reassortant influenza A viruses generated by reverse
genetics.
Serial No. Virus name (subtype)
# Clade Host
1 A/Hongkong/156/97 (H5N1) 0 Human
2 A/HongKong/213/03 (H5N1) 1 Human
3 A/Vietnam/1203/04 (H5N1) 1 Human
4 A/Indonesia/CDC1031/07 (H5N1) 2.1 Human
5 A/turkey/Turkey1/05 (H5N1) 2.2 Avian
6 A/barheaded goose/Qinghai/12/05(H5N1) 2.2 Avian
7 A/Nigeria/6e/07(H5N1) 2.2 Human
8 A/Egypt/0636-NAMRU3/07(H5N1) 2.2 Human
9 A/Anhui/1/05 (H5N1) 2.3 Human
10 A/chicken/Nongkhai/NIAH400802/07 (H5N1) 2.3 Avian
11 A/VietNam/HN31242/07 (H5N1) 2.3 Human
12 A/goose/Guiyang/337/06 (H5N1) 4 Avian
13 A/chicken/Shanxi/2/06 (H5N1)
14 A/chicken/Henan/12/04 (H5N1) 8 Avian
#Donor of HA and NA genes for derivation of PR8 reassortant viruses.
doi:10.1371/journal.pone.0005672.t001
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Hemagglutination inhibition (HI) assays were performed as
described previously [22]. Briefly, mAbs were serially diluted (2
fold) in V-bottom 96-well plates and mixed with 4 HA units of
virus (A/Indonesia/TLL013/06). Plates were incubated for
30 min at room temperature, and 1% chicken RBCs were added
to each well. The hemagglutination inhibition endpoint was the
highest mAb dilution in which agglutination was not observed.
Isolation and analysis of escape mutants
The epitope recognized by mAb 2D9 and 4C2 were mapped by
characterization of escape mutants as described previously [23].
Briefly, H5N1 viruses were incubated with an excess of mAb for
1 h and then inoculated into 11 day old embryonated chicken
eggs. For isolation of in vivo escape mutants, the lung samples from
the treated mice were inoculated directly into the embryonated
eggs. The eggs were incubated at 37uC for 48 h. Virus was
harvested and used for cloning in limiting dilution in embryonated
chicken eggs and the escape mutants were plaque purified. The
HA gene mutations were then identified by sequencing and
comparing with the sequence of the parent virus.
Cloning of chimeric IgG1 expression plasmid
Design of the expression vector was as described [24]. Briefly,
human antibody constant regions encoding the kappa light chain
and the IgG1 heavy chain were amplified and cloned into a
modified pCMV/myc/ER plasmid with an internal ribosome
entry site (IRES) of encephalomyocarditis virus inserted in
between them. Unique restriction sites were introduced to allow
for insertion of the variable regions of the heavy and light chains in
frame with the constant regions.
mRNA was prepared from the mAb 4C2 and 2D9 hybridoma
cells and used in first strand cDNA synthesis with random
hexamers. The total cDNA was used as template to amplify both
the variable heavy and light chain using the primers and protocols
of the mouse scFv recombinant antibody phage system (Amersham
Biosciences). The resultant products were cloned into pCR-Script
(Stratagene, USA) for sequencing. Sequence-specific primers were
then designed and used for amplification of the variable regions,
which were then cloned into the expression vector. Expression of
this construct lead to the production of chimeric antibodies
containing 33% of the sequences as mouse variable regions from
murine and 67% of the sequences as human constant regions for
IgG1.
Transient expression of chimeric antibodies and
purification
Chimeric antibodies were expressed using the Freestyle 293
Expression system (Invitrogen, USA) to obtain antibodies
produced in a defined, serum-free medium. The above mentioned
construct was transfected into 293-F cells using 293fectin
(Invitrogen, USA) and supernatants were collected 120 h after
transfection. The chimeric antibodies 4C2 (ch-mAb 4C2) and 2D9
(ch-mAb 2D9) were purified using Protein A sepharose beads
(Millipore). Purity of the chimeric antibodies were confirmed by
SDS-PAGE and immunoblot analysis using HRP labeled anti-
human Ig (DAKO) was used to confirm introduction of human
constant regions.
Microneutralization assay
Neutralization activity of the chimeric antibodies against H5N1
strains was analyzed by microneutralization assay as previously
described [25,26]. Briefly, mAb was serially two-fold diluted and
incubated with 100 50% tissue culture infectious doses (TCID50)o f
different clades of H5N1 strains for 1 h at room temperature and
plated in duplicate onto MDCK cells grown in a 96-well plate.
The TCID50 of each of the H5N1 strains in MDCK cell culture
was determined by the Reed and Muench method [27]. The
neutralizing titer was assessed as the highest mAb dilution in which
no cytopathic effect was observed by light microscopy.
Immunization and Challenge
Groups of SPF female BALB/c mice aged 4–6 weeks were used
for the challenge studies. Mice (n=10 per group) were inoculated
intranasally with 10 MLD50 (Mouse lethal dose 50%) of two
different H5N1 strains (A/Vietnam/1203/2004 from clade 1 and
A/Indonesia/TLL013/06 from clade 2.1). All animal experiments
were carried out in accordance with the guides for animal
experiments performed at NIID and experimental protocols were
reviewed and approved by Institutional Animal Care and Use
Committee at Temasek Life Sciences Laboratory, National
University of Singapore.
Prophylactic efficacy
To determine the prophylactic efficacy, mice were pre-treated
intraperitoneally with 1.0 mg/kg, 2.5 mg/kg, 5 mg/kg or 0 mg/
kg (PBS) of the combination of ch- mAbs, prior to the viral
challenge. 5 mg/kg of an irrelevant IgG1 monoclonal antibody
8C2 (specific for porcine circovirus), prepared in a similar manner
was used to measure any non-specific protection. After 24 h, mice
were challenged with 10 MLD50 of the two different H5N1 strains.
Mice were observed daily to monitor body weight and mortality
until all animals died or until day 14 after challenge.
Therapeutic efficacy
To determine the therapeutic efficacy of the ch-mAb, each
group of mice was experimentally infected with 10 MLD50 of the
two different H5N1 strains. Twenty four hours after viral
infection, the mice were treated via intra-peritoneal route with
1.0 mg/kg, 2.5 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of the
combination of ch-mAbs. 5 mg/kg of an irrelevant monoclonal
antibody 8C2 (specific for porcine circovirus) prepared in a similar
manner was used to measure any non-specific protection. For the
double therapy experiment, different sets of mice were treated with
similar doses of chimeric mAbs 24 h and 72 h after the viral
challenge.
One additional group of mice was challenged with 10 MLD50 of
H5N1 virus from clade 2.1 and treated one day after viral
challenge with ch-mAb 2D9. This was done to compare the
therapeutic efficacy of one mAb against that of the combination of
ch-mAbs.
Separate sets of mice were maintained for each experimental
group infected with clade 1.0 for determination of viral titers and
histopathology experiments. On day 3, 6 and 9 post viral
challenges, mice were euthanized by a lethal dose of sodium
pentobarbital. For determination of viral titers, lungs were
aseptically removed. Tissues were homogenized in 1 ml Dulbec-
co’s Minimal Essential Medium (DMEM) supplemented with
antibiotic-antimycotic solution (Gibco-BRL, USA) to achieve 10-
fold serially diluted suspensions of lung samples and were titrated
on monolayers of MDCK cells. The viral titers were calculated by
use of the method of Reed and Muench method [27] and
expressed as log10 TCID50/gram of tissue 6S.E. The limit of virus
detection was 1.5 log10 TCID50/gram of lung tissue specimen.
For histopathology, mice were necropsied and the lungs were
stored in 10% (wt/vol) neutral buffered formalin and embedded in
paraffin and sectioned. Sections were stained with hematoxylin
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evaluated for lung pathology.
Results
Selection of a pair of complementing monoclonal
antibodies
A panel of seven neutralizing mAbs against influenza hemag-
glutinin (HA) was screened for high hemagglutination inhibition
titers against different clades of H5N1 viruses. Based on the results
of the HI assay, mAbs 2D9 and 4C2 were chosen for further
studies due to their high HI activity (data not shown) against a
wide range of rescued reassortant viruses from different clades.
Both mAbs were found to be of the IgG1 isotype. The amino acids
involved in forming the epitopes of the mAbs were analyzed using
selection of neutralization escape mutants. Sequencing of the
complete HA gene isolated from multiple escape variants to
mAb2D9 carried single point mutations at amino acid positions
189 (Arg to Trp) or 223 (Ser to Arg) (excluding signal peptide).
Similar analysis for mAb 4C2 revealed the involvement of amino
acid 155 (Ser to Asn) in forming the epitope.
The two mAbs were found to recognize non-overlapping
epitopes and reacted with all the H5N1 viruses from different
clades available in our laboratory. Further, escape mutants to mAb
2D9 were recognized by mAb 4C2 and vice versa. Hence, these
mAbs were thought to have good potential for being used in
combination as therapy against H5N1 infections. To further
ascertain this, the mAbs in combination were subjected to
hemagglutination inhibition assays against a wide range of
H5N1 viruses from different clades. Hemagglutination inhibition
assays using a combination of these mAbs elicited a titer of 128–
512 with all the tested H5N1 strains (Table 2). It was then
concluded that the mAbs 2D9 and 4C2 complemented each other
and were a good pair to use in therapy against H5N1 influenza.
Chimeric monoclonal antibodies (ch-mAbs) were generated for
both the mAbs such that the constant regions were replaced with
those from human origin but variable regions remained from
murine origin. The chimeric mAbs generated in this way were
66.6% humanized. The chimeric antibodies still retained the
original properties of the murine mAbs (results not shown). The in
vitro microneutralization titers dropped a little compared to the
murine mAbs but still retained significant viral neutralization
activity (Table 3).
Prophylactic potential of the combination of chimeric
mAbs
The prophylactic efficacy of the combination of 2D9 and 4C2
ch-mAbs was evaluated against challenge with 10 MLD50 of clade
1 or clade 2.1 viruses. Groups of mice (n=10) were inoculated via
intraperitoneal route with different concentrations (1 mg/kg,
2.5 mg/kg and 5 mg/kg) of the combination of mAbs, 24 h prior
to viral challenge. The negative control group of mice (treated with
non-specific mAbs) showed the most rapid decline in body weight
(above 25%) and died from complications associated with infection
by day 6 post challenge. The group of mice which was pre-treated
with a single dose of 5 mg/kg ch-mAbs showed less than 7%
(Fig. 1C and 1D) loss of body weight and this concentration
provided 100% protection against 10 MLD50 of both clades of
viruses (Fig. 1A and 1B). Moreover, ch-mAbs at 2.5 mg/kg
provided sufficient protection (90%) in a dose dependent manner
and this group of mice showed less than 12% loss of body weight.
Even at a very low concentration of 1 mg/kg, the ch-mAbs could
provide 60% and 70% protection against clade 1(Fig. 1A) and
clade 2.1(Fig. 1B) viruses respectively. The mice in these groups
showed a loss of body weight of up to 15% (Fig. 1C and 1D).
Therapeutic potential of a single mAb against viral
challenge
In order to evaluate the therapeutic potential of a single mAb
against H5N1 influenza infection, we treated the mice with ch-
mAb 2D9 alone, one day after viral challenge against 10MLD50
of H5N1 virus. We observed that 10 mg/kg of 2D9 ch-mAb
(Fig. 2) could protect 100% of the mice from viral infection.
Table 2. Hemagglutination Inhibition (HI) titers of the mAbs
against H5N1 influenza viruses.
H5N1 strain Clade HI titers of the mAbs
2D9
a 4C2
a 2D9+4C2
b
A/Hongkong/156/97 0 128 256 256
A/HongKong/213/03 1 512 256 512
A/Vietnam/1203/04 1 512 512 512
A/Indonesia/TLL014/06 2.1 128 256 256
A/Indonesia/CDC540/06 2.1 256 ,81 2 8
A/Indonesia/CDC669/06 2.1 512 256 512
A/Indonesia/CDC1031/07 2.1 256 512 512
A/turkey/Turkey1/05 2.2 256 128 256
A/barheaded goose/Qinghai/12/05 2.2 256 128 256
A/Nigeria/6e/07 2.2 128 64 128
A/Egypt/0636-NAMRU3/07 2.2 64 256 128
A/Anhui/1/05 2.3 512 256 512
A/chicken/Nongkhai/NIAH400802/07 2.3 256 128 256
A/VietNam/HN31242/07 2.3 512 128 256
A/goose/Guiyang/337/06 4 128 256 256
A/chicken/Shanxi/2/06 7 256 64 128
A/chicken/Henan/12/04 8 256 256 512
EM* 2D9 mAb A/Indonesia/CDC669/06 ,8 256 128
EM* 4C2 mAb A/Indonesia/CDC669/06 512 ,82 5 6
aConcentration of mAb at 500 mg/ml.
bConcentration of each mAb at 250 mg/ml.
*EM indicates Escape Mutant against the mAb mentioned.
doi:10.1371/journal.pone.0005672.t002
Table 3. Microneutralization titers of the murine and
chimeric mAbs against H5N1 influenza viruses.
H5N1 straina Clade MicroneutralizationtitersofthemAbs
2D9+4C2 Murine
mAbs
b
2D9+4C2
ch-mAbs
b
A/HongKong/213/03 1 640 320
A/Indonesia/CDC594/06 2.1 320 320
A/Anhui/1/05 2.3 320 160
A/goose/Guiyang/337/06 4 320 320
A/chicken/Henan/12/04 8 320 160
a100 TCID50 of each virus strain used for microneutralization assay.
bConcentration of each mAb at 250 mg/ml.
doi:10.1371/journal.pone.0005672.t003
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5672Figure 1. Prophylactic efficacy of the combination of chimeric mAbs in mice. Groups of mice (n=10) were pre-treated intraperitoneally
with 1 mg/kg, 2.5 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of the combination of ch-mAbs, one day before challenge with 10MLD50 of mouse-adapted
HPAI H5N1 from A/Vietnam/1203/2004 (A and C) or clade 2.1 virus A/TLL013/06 (B and D). An irrelevant IgG1 monoclonal antibody (specific for
porcine circovirus) was used as a negative control. Mice were monitored for survival (A and B) and weight loss (C and D) throughout a 14 day
observation period. The results are expressed in terms of percent survival and percent body weight (at the beginning of the trial) respectively.
doi:10.1371/journal.pone.0005672.g001
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5 mg/kg and 2.5 mg of therapeutic antibody respectively.
Therapeutic potential of single dose versus two doses of
the combination of chimeric mAbs
To determine if a single dose of treatment could elicit efficient
protection against lethal viral infection, one set of mice were
treated with a single dose (24 h after viral challenge) of mAbs. The
efficacy of this single dose was compared with that in mice treated
with double dose (24 h & 72 h after viral infection) of ch-mAbs.
Groups of mice treated with either single dose or double dose of
5 mg/kg ch-mAbs lost less than 5% of their original body weight
by day 4 after challenge and provided 100% protection against
both clade 1(Fig. 3A and 3C) and 2.1 viruses (Fig. 3B and 3D).
Moreover, the group of mice that received the double dose of ch-
mAbs (at 48 hour intervals) regained their body weight more
rapidly (within 6 days) when compared to the mice that received a
single dose, which regained their body weight only 10–12 days
after the viral infection (Fig. 3C and 3D).
Mice treated with double dose of 2.5 mg/kg ch-mAbs also lost
less than 5% of their original body weight and provided 100%
protection against both H5N1 viruses. However, mice treated with
a single dose of the same concentration of ch-mAbs showed
considerable weight loss (up to 10%) and provided only 80%
protection. Even at very low concentrations of 1 mg/kg, two doses
of the combination of ch-mAbs could provide 80% protection
against 10 MLD 50 of both H5N1 viruses. In contrast, mice
treated with a single dose of the same concentration showed a loss
in body weight of up to 15% (Fig. 3C and 3D) and provided only
moderate protection (60–70%) against H5N1 viruses (Fig. 3A and
3B).
Histopathology studies were followed only for the lungs of mice
treated with single and double doses of the combination of mAbs
24 h post viral infection with clade 1 virus. On day 6 p.i., lungs of
untreated mice or mice treated with irrelevant mAb had
pulmonary lesions consisting of moderate to severe necrotizing
bronchitis, moderate to severe histiocytic alveolitis with associated
pulmonary edema (Fig. 4B). The uninfected mice lacked lesions in
the lungs (Fig. 4A). Mice treated with two doses of 5 mg/kg
showed no lung pathology and looked similar to the uninfected
control (Fig. 4D). Mice treated with a single dose of with 5 mg/kg
of ch-mAbs had minimal bronchitis (Fig. 4C).
We studied the kinetics of viral replication by measuring the
viral titers in the lungs of infected and treated mice on days 3, 6
and 9. The virus titers were most elevated on day 3 after viral
challenge. Viral titers were highest in the infected but untreated
control on day 3 and all the animals succumbed to the infection by
day 6 after viral challenge (Fig. 5). The mice treated with a single
dose of 5 mg/kg of the combination and those treated with double
dose of 2.5 mg/kg or 5 mg/kg showed undetectable viral titers by
day 6. However those mice treated with the other doses showed
undetectable titers only by day 9 (Fig. 5). However on day 6, the
mice treated with 2 doses of 1 mg/kg had much lower viral titers
than those treated with single doses. These results show that even
at lowest concentrations of 1 mg/kg, a double dose of the mAb
combination could neutralize the virus much efficiently than a
single dose (Fig. 5).
Escape mutants were isolated from the lungs of 20% of the mice
after treatment with single dose of ch-mAbs, even at concentra-
tions of 5 mg/kg. These Escape mutants were found to have a
common mutation at Ser 155. Escape mutants were observed in
80% of mice when treated with 2.5 mg/kg of ch-mAbs. Among
these, majority of the individual mice (75%) showed single point
mutants that escaped the mAb and very few mice (25%) showed
escape mutants with mutations at two points (Ser155 and Arg189).
Interestingly, no escape mutants were isolated from the lungs of
the groups of mice treated with double doses of ch-mAbs at 48 h
intervals.
Discussion
Highly neutralizing antibody responses for protective immunity
against influenza infections have been associated with the
hemagglutinin (HA) glycoprotein. Therefore, this protein has
been a major focus for therapeutic intervention in influenza
infections. Most of the influenza vaccines target this protein to
induce immune responses in the host, mainly in the form of
neutralizing antibody based response [25]. However, whenever
immediate protection becomes essential and there is no time to
induce an antibody response, the best alternative so far is passive
immunization. Also, since drug resistant strains of H5N1 viruses
are emergent, it is vital to explore other means of therapy for
H5N1 infections [9]. Passive monoclonal antibody based therapy
is a viable option that can be investigated.
Previous studies have proven the efficacy of humanized and
human monoclonal antibodies as therapy in murine models of
H5N1 infection [11,12]. However, these studies only discuss the
application of single monoclonal antibodies against infections with
some strains of H5N1 virus. A single monoclonal antibody may
not be sufficient to protect against all circulating strains [33]. Also,
Figure 2. Therapeutic potential of a single mAb against H5N1
influenza infection in mice. Groups of mice (n=10) were infected
with mouse-adapted HPAI H5N1 from clade 2.1 virus A/TLL013/06.
Twenty fours after viral challenge, the mice were treated via intra-
peritoneal route with 2.5 mg/kg, 5 mg/kg, 10 mg/kg or 0 mg/kg (PBS)
of a single ch-mAb 2D9. Mice were monitored for survival throughout a
14 day observation period. The results are expressed in terms of percent
survival.
doi:10.1371/journal.pone.0005672.g002
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5672Figure 3. Therapeutic potential of one versus two doses of the combination of chimeric mAbs in mice. Groups of mice (n=10) were
infected with mouse-adapted HPAI H5N1 from Clade 1 A/Vietnam/1203/2004 (A and C) and clade 2.1 virus A/TLL013/06 (B and D). For treatment with
a single dose, 24 h after viral challenge, the mice were treated via intra-peritoneal route with 1.0 mg/kg, 2.5 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of the
combination of mAbs. For treatment with two doses, different sets of mice were treated twice with similar doses of chimeric mAbs 24 h and 72 h
after the viral challenge. An irrelevant IgG1 monoclonal antibody (specific for porcine circovirus) was used as a negative control. Mice were monitored
for survival (A and B) and weight loss (C and D) throughout a 14 day observation period. The results are expressed in terms of percent survival and
percent body weight (at the beginning of the trial) respectively.
doi:10.1371/journal.pone.0005672.g003
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pressure-induced ‘‘escape’’ of the virus through point mutations
that can alter antibody binding [14]. The above mentioned studies
with H5N1 infections have not looked into this aspect in great
detail. In view of the proven efficiency of passive prophylaxis and
therapy of H5N1 infection in animal models using single mAbs, we
evaluated the prospect of using a combination of monoclonal
antibodies to tackle the issues posed by using single mAbs as
therapy. As is evident from our studies, the synergistic action of
two or more mAbs in combination is required for preventing the
generation of escape mutants and also to enhance the therapeutic
efficacy against H5N1 infection.
We chose the mAbs based on their recognition of non-
overlapping and non-competing epitopes. In combination, mAbs
2D9 and 4C2 could neutralize all of the strains from phylogenet-
ically distinct clades 0, 1, 2.1, 2.2, 2.3, 4, 7 and 8. Also, the escape
mutants generated from each of these mAbs could be efficiently
neutralized by the other. We deduced that the combination of
these mAbs would be very efficient in therapy against most strains
of H5N1. Hence, we used the combination of these mAbs for
prophylaxis and therapy against H5N1 in a mouse model of
infection.
The results of the present study demonstrate that passive
administration of a combination of two different neutralizing
chimeric mAbs against HA1 can effectively protect against highly
pathogenic H5N1 infection, when administered either as prophy-
laxis or therapeutics. We observed that 10 mg/kg of ch-mAb was
required for the protection of 100% of the mice when a single
mAb was used. However, when the combination of mAbs was
used under the same conditions of viral challenge, only 5 mg/kg of
a single dose or 2.5 mg/kg of the double dose was needed to offer
complete protection. Administration of two doses of the combi-
nation showed better protection as the viral loads in the lungs were
significantly reduced when compared to administration of a single
dose. Moreover, a double dose of the combination of mAbs
controlled immune escape as no escape mutants were isolated
from the lungs of the groups of mice treated at 48 h intervals with
two doses.
We observed the generation of escape mutants in vivo in 100%
of the cases whenever a single monoclonal antibody was used
for therapy (data not shown). However, using two mono-
clonal antibodies in combination also showed the generation
of escape mutants whenever sub-neutralizing concentrations of
mAbs were used. Using higher concentrations in a single
Figure 4. Histopathology of lung tissue in passively treated
mice. Photomicrographs of hematoxylin and eosin stained lung
sections of mice treated with single or double doses of the combination
of mAbs after post experimental viral infection with Clade 1 A/Vietnam/
1203/2004 H5N1 virus at 6 days post challenge. A) Normal morphology
seen in uninfected mice, B) infected and untreated mice, C) mice
treated with a single dose of 5 mg/kg of ch-mAbs at 24 h post
infection, D) mice treated with two doses of 5 mg/kg of ch-mAbs at
24 h and 72 h post infection.
doi:10.1371/journal.pone.0005672.g004
Figure 5. Measurement of viral infectivity titers in the lungs of
mice experimentally infected with HPAI H5N1 (A/Vietnam/
1203/2004- Clade 1) virus. For single dose treatment, 24 h after viral
challenge, the mice were treated via intra-peritoneal route with 1.0 mg/
kg, 2.5 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of the combination of mAbs.
For the double therapy experiment, different sets of mice were treated
with similar doses of chimeric mAbs 24 h and 72 h after the viral
challenge. The viral loads were measured in the lungs of the infected
animals on days 3, 6 and 9 post challenge. The results are expressed in
terms of mean value of log TCID50/g6(S.E). (# represents no survival of
any animals in the group and & represents undetectable viral titers). The
lower limit of detection was 1.5 log10 TCID50/g.
doi:10.1371/journal.pone.0005672.g005
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dependent on the amount of the complementary circulating
mAb present in the system which could effectively neutralize
the escape mutants due to any one of the mAb. Based on the
evidence from the body weight of the mice, the mice were
healthy enough from the single administration for the escape
mutants to be cleared by the active immune system of the
mice. Given that the half life of the mAbs is limited, it is evident
as to why two doses of the mAb combination worked in a
much better way and provided better safety against the emer-
gence of escape variants. The high rate of emergence of escape
mutants to these viruses are evidence that the antibodies are
highly neutralizing and hence forcing the viruses to adapt. But
the fact that using both ch-mAbs in combination in two doses
did not give rise to any escape mutants is proof that the antibodies
are complementary and hence offer complete protection to the
mice.
Previous studies with other viruses have shown that combina-
tion of two or more than two mAbs directed against different
epitopes could lead to a two to ten fold increase in neutralization
titers [28,29] and provided greater protection against many other
diseases [30,31,32]. Moreover, Meulen et al. [33] reported that
much better control of potential neutralization escape variants
could be achieved with an antibody combination against SARS
Coronavirus. However, no studies have been done so far to
demonstrate the efficacy of combination therapy against H5N1
infection.
Though the dose of antibodies delivered for complete protection
of mice was quite high, we believe that further improvement of
these antibodies as well as their inclusion in an antibody cocktail
will ensure better protection. Our data provide a rationale to
develop combinations of mAbs for human H5N1 prophylaxis and
therapeutics. The combination of two mAbs expanded the breadth
of protection with a high level of efficacy and safety associated with
potential immune escape variants. Also, combination therapy may
allow for a lower dose of antibody to be administered for passive
therapy of influenza infection and hence can be made available at
reduced economic costs during an outbreak. In future, it may be
possible to generate humanized monoclonal antibodies of mAb
2D9 and 4C2 by CDR (Complementarity Determining Regions)
grafting and further facilitate their use in non-primate and human
clinical trials.
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